{"id":4362,"date":"2025-08-25T16:43:15","date_gmt":"2025-08-25T13:43:15","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4362"},"modified":"2025-08-25T16:46:42","modified_gmt":"2025-08-25T13:46:42","slug":"duvyzat-givinostat-positive-long-term-data-from-phase-2-and-phase-3-epidys-trials","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/duvyzat-givinostat-positive-long-term-data-from-phase-2-and-phase-3-epidys-trials\/","title":{"rendered":"ITF Therapeutics, Duvyzat'\u0131n (Givinostat) Duchenne Kas Distrofisi Tedavisinde Etkinli\u011fini ve G\u00fcvenli\u011fini Destekleyen Olumlu Uzun Vadeli Verilerin Yay\u0131nland\u0131\u011f\u0131n\u0131 Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Italfarmaco'nun i\u015ftiraki olan ITF Therapeutics, bug\u00fcn \u015firketin Faz 2 ve Faz 3 (EPIDYS) denemelerinin a\u00e7\u0131k etiketli uzant\u0131lar\u0131ndan Duchenne kas distrofisi (DMD) tedavisi i\u00e7in Duvyzat'\u0131n (Givinostat) uzun vadeli olumlu g\u00fcvenlik ve etkinlik verilerinin yay\u0131nland\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Annals of Clinical and Translational Neurology dergisinde yay\u0131mlanan sonu\u00e7lar, yeni bir histon deasetilaz (HDAC) inhibit\u00f6r\u00fc olan givinostat ile kortikosteroidlerin kombinasyonunun uzun s\u00fcreli tedavisinin, alt\u0131 ya\u015f ve \u00fczeri DMD&#039;li ayaktan hastalarda hastal\u0131\u011f\u0131n ilerlemesini geciktirdi\u011fini g\u00f6stermektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duvyzat (Givinostat) Nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha da \u00f6nemlisi, givinostat alan tedavi gruplar\u0131nda klinik fayda g\u00f6zlemlenmi\u015f olup, yerden kalkma, merdiven \u00e7\u0131kma ve y\u00fcr\u00fcme (hareket etme) yetene\u011fi gibi temel hareketlilik i\u015flevleri \u00fczerinde olumlu etki g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Givinostat, ABD, AB ve Birle\u015fik Krall\u0131k&#039;ta pazarlama yetkisi alm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Annals of Clinical and Translational Neurology dergisinde yay\u0131mlanan yeni veriler, givinostat ile uzun s\u00fcreli tedavinin Duchenne kas distrofisi hastalar\u0131nda temel hareket fonksiyonlar\u0131n\u0131n kayb\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geciktirebilece\u011fini g\u00f6steriyor.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ba\u015flang\u0131\u00e7taki hastal\u0131k evresinden ba\u011f\u0131ms\u0131z olarak, tedavi gruplar\u0131nda anlaml\u0131 klinik fayda g\u00f6zlendi.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Givinostat, daha \u00f6nceki klinik \u00e7al\u0131\u015fmalarla tutarl\u0131 olarak, uzun s\u00fcreli kullan\u0131mda iyi tolere edildi.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Uzatma \u00e7al\u0131\u015fmas\u0131nda ortalama takip s\u00fcresi 36 tedavi ay\u0131n\u0131 a\u015ft\u0131 ve baz\u0131 hastalar givinostat tedavisine ba\u015flad\u0131ktan sonra sekiz y\u0131ldan fazla s\u00fcre tedavi g\u00f6rd\u00fc.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fmaya, hepsi farkl\u0131 s\u00fcrelerde givinostat alan DMD&#039;li erkek \u00e7ocuklardan olu\u015fan birden fazla grup dahil edildi. Baz\u0131lar\u0131, uzatma \u00e7al\u0131\u015fmas\u0131na kat\u0131lmadan \u00f6nce Faz 2 veya Faz 3 EPIDYS \u00e7al\u0131\u015fmalar\u0131na (aktif tedavi veya plasebo) kat\u0131lm\u0131\u015ft\u0131. Di\u011ferleri ise, ana \u00e7al\u0131\u015fmaya kat\u0131lmadan uygunluk kriterlerini kar\u015f\u0131lad\u0131ktan sonra do\u011frudan uzatma \u00e7al\u0131\u015fmas\u0131na kaydoldu. Baz\u0131 hastalar\u0131n toplam tedavi s\u00fcresi sekiz y\u0131l\u0131 a\u015ft\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/itf-therapeutics-launching-a-study-to-evaluate-the-real-world-experience-of-duvyzat-givinostat-in-patients-with-duchenne-muscular-dystrophy\/\">ITF Therapeutics, Duchenne Musk\u00fcler Distrofisi Olan Hastalarda Duvyzat'\u0131n (Givinostat) Ger\u00e7ek D\u00fcnya Deneyimini De\u011ferlendirmek \u0130\u00e7in Bir \u00c7al\u0131\u015fma Ba\u015flat\u0131yor<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ITF Therapeutics affiliate of Italfarmaco, today announced publication of positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular dystrophy (DMD) from the company&#8217;s open-label extensions of its Phase 2 and Phase 3 (EPIDYS) trials. The results, published in Annals of Clinical and Translational Neurology, show that long-term treatment with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4366,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[46,47,300],"class_list":["post-4362","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duvyzat","tag-givinostat","tag-itf-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4362"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4366"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}